US Firm Committed to Promote Honey Wound Treatment Product Line

Derma Sciences CEO Stresses Commitment to Manuka Honey for Wound Care at Comvita Ltd. Annual Meeting
Business Wire, 4/23/2007

Derma Sciences, Inc. (OTCBB: DSCI), a manufacturer and supplier of wound and skin care products, announced that Chairman, President and CEO Edward J. Quilty spoke at the April 20, 2007 annual meeting of Comvita LTD, a New Zealand based natural health products company. Derma Sciences is Comvita Ltd.'s worldwide manufacturing and marketing partner for Active Manuka Honey based wound care products, manufacturing and marketing the Derma Sciences' API-MED brand in North, South, Central and Latin America, while manufacturing and marketing for the global market under the Comvita name. Quilty was introduced by Comvita's CEO Brett Hewlett and he discussed Derma's strategy before approximately 200 Comvita shareholders. Quilty's presence in New Zealand was in conjunction with his attendance at Comvita's global product launch conference where thought leaders from around the world discussed the antimicrobial and wound healing properties of Active Manuka Honey.

Quilty's comments at the Comvita annual meeting conveyed Derma Science's commitment to the Active Manuka Honey product line, stating that upon FDA clearance of Derma Sciences' Active Manuka Honey based dressing (currently under review), the Company plans a major launch of the product under the API-MED brand as part of Derma Sciences overall strategy to advance wound care through the use of innovative technology. Derma Sciences plans to add nine new sales representatives in North America, bringing to 15 the total number of reps, and to add to that number as the product gains market acceptance. The initial target market for Derma Sciences' Active Manuka Honey based product line is expected to be the current market for Silver based dressings. The global market for Silver based dressings is estimated to be $150 million annually…